Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Cell Procurement

A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma

Bone Marrow Transplantation volume 43, pages 101–105 (2009)Cite this article

Abstract

Some reports have suggested that rituximab administration before PBSC mobilization may adversely affect PBSC yield. We conducted a prospective randomized trial of PBSC mobilization using etoposide and G-CSF with or without rituximab to determine whether its addition would adversely affect CD34+ cell yield in patients with non-Hodgkin's lymphoma. Twenty seven patients were mobilized with etoposide and G-CSF and 28 with etoposide, G-CSF and rituximab. There were no adverse consequences of rituximab on CD34+ cell yield, or hematopoietic recovery or immunoglobulin levels after transplantation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Benekli M, Hahn T, Shafi F, Qureshi A, Alam AR, Czuczman MS et al. Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients. Bone Marrow Transplant 2003; 32: 139–143.

    Article  CAS  PubMed  Google Scholar 

  2. Hoerr A, Gao F, Hidalgo J, Tiwari D, Blum K, Vikram M et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 4561–4566.

    Article  CAS  PubMed  Google Scholar 

  3. Buckstein R, Imrie K, Spaner D, Potichnyi A, Robinson JB, Nanji S et al. Stem cell function and engraftment is not affected by ‘in vivo purging’ with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin Oncol 1999; 26 (5 Suppl 14): 115–122.

    CAS  PubMed  Google Scholar 

  4. Hosing C, Saliba RM, Korbling M, Acholonu S, McMannis J, Anderlini P et al. High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 2006; 47: 1290–1294.

    Article  CAS  PubMed  Google Scholar 

  5. de Latour RP, Chaoui D, Bourhis JH, Belhocine R, Park S, Legrand O et al. Mobilization of peripheral blood progenitor cells after DHAP regimen with or without Rituximab: a large multicenter comparative study in patients with malignant lymphoma. Leuk Lymphoma 2007; 48: 897–904.

    Article  CAS  PubMed  Google Scholar 

  6. Kamezaki K, Kikushige Y, Numata T, Miyamoto T, Takase K, Henzan H et al. Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma. Bone Marrow Transplant 2007; 39: 523–527.

    Article  CAS  PubMed  Google Scholar 

  7. Copelan EA, Ceselski SK, Ezzone SA, Lasky LC, Penza SL, Bechtel TP et al. Mobilization of peripheral blood progenitor cells with high dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease. J Clin Oncol 1997; 15: 759–765.

    Article  CAS  PubMed  Google Scholar 

  8. Avery RK, Pohlman BL, Mossad SB, Goormastic M, Longworth DL, Kalaycio ME et al. The efficacy of prophylactic outpatient antibiotics for the prevention of neutropenic fever associated with high-dose etoposide (VP-16) for stem cell mobilization. Bone Marrow Transplant 2002; 30: 311–314.

    Article  CAS  PubMed  Google Scholar 

  9. Copelan EA, Penza SL, Pohlman B, Avalos BR, Goormastic M, Andresen SW et al. Autotransplantation following busulfan, etoposide, and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2005; 25: 1243–1248.

    Article  Google Scholar 

  10. Sharp JG, Kessinger A, Mann S, Crouse DA, Armitage JO, Bierman P et al. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumour in the marrow or infused hematopoietic harvest. J Clin Oncol 1996; 14: 214–219.

    Article  CAS  PubMed  Google Scholar 

  11. Jacobsen E, Freedman A . B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphoma. Lancet Oncol 2004; 5: 711–717.

    Article  CAS  PubMed  Google Scholar 

  12. Van Heeckeren WJ, Vollweiler J, Fu P, Cooper BW, Meyerson H, Lazarus HM et al. Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34+ cell enrichment device. Br J Haematol 2005; 132: 42–55.

    Article  Google Scholar 

  13. Ladetto M, Zallio F, Vallet S, Ricca I, Cuttica A, Caracciolo D et al. Concurrent administration of high-dose chemotherapy and rituximab is feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. Leukemia 2001; 15: 1941–1949.

    Article  CAS  PubMed  Google Scholar 

  14. Koc ON, Gerson SL, Cooper BW, Laughlin M, Meyerson H, Kutteh L et al. Randomized cross-over trial of progenitor-cell mobilization: high dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol 2000; 18: 1824–1830.

    Article  CAS  PubMed  Google Scholar 

  15. Boeve S, Strupeck J, Creech S, Stiff PJ . Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost. Bone Marrow Transplant 2004; 33: 997–1003.

    Article  CAS  PubMed  Google Scholar 

  16. Chabannon C, Le Corroller AG, Viret F, Eillen C, Faucher C, Moatti JP et al. Cost-effectiveness of repeated aphereses in poor mobilizers undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation. Leukemia 2003; 17: 811–813.

    Article  CAS  PubMed  Google Scholar 

  17. Tomblyn M, Burns LJ, Blazar B, Wagner J, Lee C, Rogers T et al. Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma. Bone Marrow Transplant 2007; 40: 111–118.

    Article  CAS  PubMed  Google Scholar 

  18. Flinn I, O'Donnell P, Vogelsang G, Abrams R, Noga S, Marcellus D et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000; 6: 628–632.

    Article  CAS  PubMed  Google Scholar 

  19. Goldberg S, Pecora A, Alter R, Kroll M, Rowley S, Waintraub S et al. Unusual viral infections (progressive multi-focal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002; 99: 1486–1488.

    Article  CAS  PubMed  Google Scholar 

  20. Lemieux B, Tartas S, Traulle C, Espinouse D, Thieblemont C, Bouafia F et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 921–923.

    Article  CAS  PubMed  Google Scholar 

  21. Goldschmidt H, Hegenbart U, Wallmeier M, Hohaus S, Haas R . Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997; 98: 736–744.

    Article  CAS  PubMed  Google Scholar 

  22. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Macro M et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131–3136.

    CAS  PubMed  Google Scholar 

  23. Tarella C, Caracciolo D, Gavarotti P, Bondesan P, Cherasco C, Omede P et al. Circulating progenitors following high-dose sequential (HDS) chemotherapy with Interverals between drug courses severely impair progenitor mobilization. Bone Marrow Transplant 1995; 16: 223–228.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA

    E Copelan, B Pohlman, M Kalaycio, R Sobecks, S Andresen, R Dean, A Koo, J Chan, J Sweetenham & B Bolwell

  2. Quantitative Health Sciences, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA

    L Rybicki

Authors
  1. E Copelan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Pohlman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Rybicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Kalaycio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Sobecks
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Andresen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Dean
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Koo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J Sweetenham
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. B Bolwell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E Copelan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Copelan, E., Pohlman, B., Rybicki, L. et al. A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 43, 101–105 (2009). https://doi.org/10.1038/bmt.2008.306

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.306

Keywords

This article is cited by

Search

Advanced search

Quick links